4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168
Citation: Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168

Immune checkpoint inhibitors in cancer therapy

Funds: 

This work was supported by The MRC DPFS grant (MR/M015696/1) and Ministry of Sciences and Technology of China (2013DFG32080).

More Information
  • Received Date: December 15, 2016
  • In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types of immunotherapy on the horizon. There has been particular focus on the immune checkpoint molecules, cytotoxic Tlymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) which have been shown to have potent immunomodulatory effects through their function as negative regulators of T cell activation. CTLA-4, through engagement with its ligands B7-1 (CD80) and B7-2 (CD86), plays a pivotal role in attenuating the activation of na?ve and memory T cells. In contrast, PD-1 is primarily involved in modulating T cell activity in peripheral tissues via its interaction with PD-L1 and PD-L2. The discovery of these negative regulators of the immune response was crucial in the development of checkpoint inhibitors. This shifted the focus from developing therapies that targeted activation of the host immune system against cancer to checkpoint inhibitors, which aimed to mediate tumor cell destruction through the removal of coinhibitory signals blocking anti tumor T cell responses.
  • Related Articles

    [1]Izzatullo Ziyoyiddin o`g`li Abdullaev, Ulugbek Gapparjanovich Gayibov, Sirojiddin Zoirovich Omonturdiev, Sobirova Fotima Azamjonovna, Sabina Narimanovna Gayibova, Takhir Fatikhovich Aripov. Molecular pathways in cardiovascular disease under hypoxia: Mechanisms, biomarkers, and therapeutic targets[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240387
    [2]Wang Siwan, Jiang Hui, Wang Jia, Wu Haisi, Wu Ting, Ni Mengnan, Zhao Qianqian, Ji You, Zhang Ziting, Tang Chunming, Xu Huae. Superior in vitro anticancer effect of biomimetic paclitaxel and triptolide co-delivery system in gastric cancer[J]. The Journal of Biomedical Research, 2021, 35(4): 327-338. DOI: 10.7555/JBR.35.20210102
    [3]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [4]Ahmad R. Safa, Mohammad Reza Saadatzadeh, Aaron A. Cohen-Gadol, Karen E. Pollok, Khadijeh Bijangi-Vishehsaraei. Emerging targets for glioblastoma stem cell therapy[J]. The Journal of Biomedical Research, 2016, 30(1): 19-31. DOI: 10.7555/JBR.30.20150100
    [5]Lintao Wang, Yanyan Peng, Kaikai Shi, Haixiao Wang, Jianlei Lu, Yanli Li, Changyan Ma. Osthole inhibits proliferation of human breast cancer cells by inducing cell cycle arrest and apoptosis[J]. The Journal of Biomedical Research, 2015, 29(2): 132-138. DOI: 10.7555/JBR.27.20120115
    [6]Di Liu, Peng Xia, Dongmei Diao, Yao Cheng, Hao Zhang, Dawei Yuan, Chen Huang, Chengxue Dang. MiRNA-429 suppresses the growth of gastric cancer cells in vitro[J]. The Journal of Biomedical Research, 2012, 26(5): 389-393. DOI: 10.7555/JBR.26.20120029
    [7]Tian Tian, Yajie Zhang, Shouyu Wang, Jianwei Zhou, Shan Xua. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer[J]. The Journal of Biomedical Research, 2012, 26(5): 336-345. DOI: 10.7555/JBR.26.20120045
    [8]Xiaoyan Wang, Guozhu Wang, Yi Zhao, Xiaoan Liu, Qiang Ding, Jingping Shi, Yin Ding, Shui Wang. STAT3 mediates resistance of CD44+CD24-/low breast cancer stem cells to tamoxifen in vitro[J]. The Journal of Biomedical Research, 2012, 26(5): 325-335. DOI: 10.7555/JBR.26.20110050
    [9]Bo Cui, Stewart P. Johnson, Nancy Bullock, Francis Ali-Osman, Darell D. Bigner, Henry S. Friedman. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells[J]. The Journal of Biomedical Research, 2010, 24(6): 424-435. DOI: 10.1016/S1674-8301(10)60057-7
    [10]Guixia?Tang, Minjun?Ji, Haiwei?Wu, Guanling?Wu. Antigen?presenting?cells?may?be?able?to?distinguish?between?normal?and?radiated?Schistosoma?japonicum?cercaria:?an?in?vitro?observation[J]. The Journal of Biomedical Research, 2010, 24(4): 285-291. DOI: 10.1016/S1674-8301(10)60040-1
  • Cited by

    Periodical cited type(1)

    1. Gawel AM, Betkowska A, Gajda E, et al. Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment. Biomedicines, 2024, 12(8): 1822. DOI:10.3390/biomedicines12081822

    Other cited types(0)

Catalog

    Article Metrics

    Article views (5700) PDF downloads (309) Cited by(1)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return